| Advanced and Metastatic Breast Cancer |
1 |
1 |
| Breast Cancer |
0 |
1 |
| Liquid Biopsy |
0 |
1 |
| Biopsy |
0 |
0.54 |
| Bone Metastasis |
0 |
0.49 |
| Circulating Tumor Cells |
0 |
0.43 |
| Genomic Medicine |
0 |
0.42 |
| Triple Negative Breast Cancer |
0 |
0.42 |
| Cancer |
0 |
0.41 |
| Metastasis |
0 |
0.4 |
| Tumor |
0 |
0.37 |
| Breast |
0 |
0.29 |
| Blood |
0 |
0.23 |
| Liver Tumor |
0 |
0.23 |
| Neoadjuvant Therapy |
0 |
0.12 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.11 |
| HIV Infection |
0 |
0.11 |
| Distant Metastasis |
0 |
0.09 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.08 |
| Tissue |
0 |
0.08 |
| Polymerase Chain Reaction |
0 |
0.06 |
| Surgery |
0 |
0.06 |
| Medical Life |
0 |
0.05 |
| Chemotherapy |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Genetics |
0 |
0.04 |
| Match |
0 |
0.04 |
| Medical Oncology |
0 |
0.04 |
| New York |
0 |
0.04 |
| Plasma |
0 |
0.04 |
| Residual Disease |
0 |
0.04 |
| Biomarker |
0 |
0.02 |
| Bone |
0 |
0.02 |
| Dorsum |
0 |
0.02 |
| Endocrine Therapy |
0 |
0.02 |
| Estrogen |
0 |
0.02 |
| Hematology |
0 |
0.02 |
| Liver |
0 |
0.02 |
| Meta-Analysis |
0 |
0.02 |
| Quality of Life |
0 |
0.02 |
| Receptors |
0 |
0.02 |
| Texas |
0 |
0.02 |